Paul Bolno, Wave Life Sciences CEO
Wave Life Sciences touts Huntington's disease win in Phase 1b/2a trial
Wave Life Sciences said Tuesday that its experimental Huntington’s disease therapy effectively lowered the mutant huntingtin protein (mHTT) levels associated with the disease in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.